Hyperglycemia: Clinical Trials

72 trials for Hyperglycemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

72 completed. 72 Phase 3, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 372Completed 72
Phase 212Completed 12

Follow Hyperglycemia: new trials by email Literature Review of Hyperglycemia trials Research Report on Hyperglycemia

Trials (filtered) newest first · largest first

All 72 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
Alpha lipoic acid, Roflumilast - Type 2 Diabetes (Adult Onset), Diabetic Neuropathies
Phase 3CompletedTanta University602022-08-012023-11-22
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Insulin glargine, NovoLog, Insulin Fiasp - Type 2 Diabetes Treated With Insulin
Phase 3CompletedBoston Medical Center1372020-12-072024-03-19
Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19
Linagliptin tablet, Insulin - Hyperglycemia, Covid19
Phase 3CompletedHospital Regional de Alta Especialidad del Bajio702020-08-012021-03-23
Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Subetta, Placebo - Impaired Glucose Tolerance
Phase 3CompletedMateria Medica Holding5382018-10-102021-02-04
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector - Pre Diabetes, Polycystic Ovary Syndrome
Phase 3CompletedWoman's882018-09-262021-06-07
Safety and Feasibility Evaluation of the APS APP
Artificial Pancreas App - Type 1 Diabetes Mellitus
Phase 2 / Phase 3CompletedSansum Diabetes Research Institute62018-02-282018-09-05
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
CGM and Insulin Pump, Closed-Loop Control System - Type 1 Diabetes Mellitus
Phase 3CompletedSansum Diabetes Research Institute322016-02-012016-10-14
Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects
Dose 1 of IQP-VV-102, Dose 2 of IQP-VV-102, Placebo - Prediabetes, Hyperglycemia
Phase 3CompletedInQpharm Group272014-06-012015-11-10
Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels
Study dietary supplement (PreCrea 600 mg capsules), Placebo - Diabetes Mellitus, Pre-Diabetes
Phase 3CompletedJoe Fenn2102013-11-012015-05-18
Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients
Human insulin isophane, Humulin N (Eli Lilly), Standard of care, Insulin lispro, Humalog (Eli Lilly) in insulin pump - Hyperglycemia
Phase 3CompletedMedical University of Vienna2632012-11-212019-02-19
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd - Diabetes Mellitus, Type 2, Hyperglycemia
Phase 3CompletedBoehringer Ingelheim14132012-10-012016-02-19
Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation
Insulin lispro, Humalog (Eli Lilly) in insulin pump, Human insulin isophane, Humulin N (Eli Lilly), Standard of care - Hyperglycemia
Phase 3CompletedMedical University of Vienna852012-08-012018-06-06
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
IV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL - Acute Ischemic Stroke, Diabetes
Phase 3CompletedUniversity of Virginia11512012-04-012019-12-23
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
Eplerenone, Spironolactone - Heart Failure, Type 2 Diabetes
Phase 3CompletedMontreal Heart Institute622012-03-012022-10-07
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
dapagliflozin, placebo - Type 2 Diabetes Mellitus, High HbA1c Level
Phase 3CompletedAstraZeneca3112011-10-012014-03-12
MAIN STUDY: Low Glycaemic Index (GI) Diet in the Management of GDM SUB-STUDY: The Breast Milk Sub-Study
Standard Care, Low GI diet - Gestational Diabetes Mellitus
Phase 2 / Phase 3CompletedUniversity of Toronto992011-10-012016-05-20
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Metformin XR plus placebo, Metformin XR plus liraglutide - Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Phase 3CompletedWoman's1532011-08-112019-07-26
A Trial of Tadalafil and Glycemic Traits
Tadalafil, Placebo - Cardiovascular Disease, Insulin Resistance
Phase 3CompletedThomas J. Wang, MD732011-08-012017-01-30
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
Dapagliflozin, Placebo - Type 2 Diabetes, High Blood Sugar
Phase 3CompletedAstraZeneca2612011-02-012014-07-24
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
Dapagliflozin - Type2 Diabetes, High Blood Sugar
Phase 3CompletedAstraZeneca7282011-02-012013-12-17

Showing 20 of 72. Sign in to see all of them.

Narrower conditions

Glucose Intolerance (32)  ·  Diabetes Mellitus, Type 2 (27)  ·  Diabetes Mellitus (16)  ·  Insulin Resistance (11)  ·  Metabolic Syndrome (9)  ·  Hypoglycemia (8)  ·  Cardiovascular Diseases (6)  ·  Obesity (5)  ·  Prediabetic State (5)  ·  Diabetes Mellitus, Type 1 (4)  ·  Hypertension (3)  ·  Overweight (3)  ·  Weight Loss (3)  ·  Coronary Artery Disease (2)

Broader conditions

Nutritional and Metabolic Diseases (72)  ·  Glucose Metabolism Disorders (70)  ·  Metabolic Diseases (70)  ·  Endocrine System Diseases (47)  ·  Diabetes Mellitus (31)  ·  Hyperinsulinism (19)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (9)  ·  Vascular Diseases (9)  ·  Body Weight (8)  ·  Insulin Resistance (8)  ·  Nutrition Disorders (8)  ·  Overnutrition (8)  ·  Cardiovascular Diseases (7)

Interventions

Metformin (12)  ·  lixisenatide (8)  ·  Rosiglitazone (6)  ·  alogliptin (4)  ·  Exercise (3)  ·  Insulin Glargine (3)  ·  Liraglutide (3)  ·  Pioglitazone (3)  ·  Ramipril (3)  ·  Standard of Care (3)  ·  Sulfonylurea Compounds (3)  ·  Vildagliptin (3)  ·  dapagliflozin (3)  ·  Arginine (2)  ·  BID protein, human (2)

Sponsors

Sanofi (9)  ·  Takeda (4)  ·  AstraZeneca (3)  ·  Novartis (3)  ·  Baylor College of Medicine (2)  ·  Gerstein, Hertzel, MD (2)  ·  IRCCS San Raffaele (2)  ·  Medical University of Vienna (2)  ·  Sansum Diabetes Research Institute (2)  ·  University of Messina (2)  ·  Woman's (2)  ·  Bayer (1)  ·  Boehringer Ingelheim (1)  ·  Boston Medical Center (1)  ·  Centre Hospitalier of Chartres (1)

Countries

United States (32)  ·  Mexico (14)  ·  Canada (13)  ·  Germany (11)  ·  Russia (11)  ·  Italy (10)  ·  India (9)  ·  Romania (8)  ·  South Korea (8)  ·  Brazil (7)  ·  Poland (7)  ·  Spain (7)  ·  Chile (6)  ·  Israel (6)  ·  Japan (6)

Top investigators

Eyal Dassau, PhD (2)  ·  Francesco Squadrito, MD (2)  ·  PierMarco Piatti, MD (2)  ·  Rubina Heptulla, MD (2)  ·  Staffan Lindeberg, MD PhD (2)  ·  Abdul Rashid A Rahman, MRCP, PhD (1)  ·  Ananda Basu, MD (1)  ·  Askiel Bruno, MD, MS (1)  ·  Bernard Zinman, MD (1)  ·  Boris Kovatchev, PhD (1)

Results publications

PMID 39963952, PMID 27267268, PMID 27319011, PMID 31956422, PMID 38770818, PMID 11832527, PMID 15793249, PMID 16855264, PMID 16980380, PMID 16997664, PMID 17310047, PMID 17583796, PMID 17898990, PMID 17909087, PMID 17947341, PMID 18268075, PMID 18544707, PMID 18839134, PMID 19114908, PMID 19131464, PMID 19171717, PMID 19477351, PMID 19640291, PMID 20573639, PMID 20634175, PMID 20634176, PMID 20682687, PMID 21118562, PMID 21428766, PMID 21515846, PMID 21733058, PMID 21852284, PMID 22059803, PMID 22082239, PMID 22179955, PMID 22215178, PMID 22291490, PMID 22419732, PMID 22424822, PMID 22432104, PMID 22442395, PMID 22442396, PMID 22443353, PMID 22564709, PMID 22683134, PMID 22686415, PMID 22686416, PMID 22692637, PMID 22751958, PMID 22836068

NIH funding

2008 (2), 2005 (1), 2009 (1), R01HL089474 (1), U01DK048489 (1), U01HL087072 (1), U01NS069498 (1)